From Analysis:
Blood-brain barrier antibody transport mechanisms
What mechanisms govern antibody transport across the blood-brain barrier and how can they be leveraged for therapeutic delivery?
Molecular Mechanism and Rationale
The low-density lipoprotein receptor (LDLR) represents a promising gateway for therapeutic delivery across the blood-brain barrier through receptor-mediated transcytosis. The LDLR belongs to the LDLR gene family and is abundantly expressed on brain capillary endothelial cells, where it normally facilitates cholesterol homeostasis through apolipoprotein B (ApoB) and apolipoprotein E (ApoE) recognition. The receptor's extracellular domain contains seven ligand-binding (LA) repeats, each approximately 40 amino acids in length and stabilized by three disulfide bonds forming a characteristic β-hairpin structure.
...No AI visual card yet
Curated pathway diagram from expert analysis
flowchart TD
A["LDLR Extracellular Domain
Lipoprotein Receptor Scaffold"]
B["Ligand-Binding Repeat Fusion
Engineered Shuttle Construct"]
C["ARH/DAB2 Endocytic Adaptors
Clathrin Internalization"]
D["Receptor-Mediated Transcytosis
Endothelial Cargo Trafficking"]
E["BBB Crossing Efficiency
Therapeutic Delivery Gain"]
F["Parenchymal Target Engagement
Cargo Reaches CNS"]
A --> B
A --> C
B --> D
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style B fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style F fill:#1b5e20,stroke:#81c784,color:#81c784
Median TPM across 13 brain regions for LDLR (LDLR gene); ARH/DAB2 adaptor proteins from GTEx v10.
Title: Leveraging LDL Receptor-Related Protein 1 (LRP1) Transcytosis for CNS Antibody Delivery
Mechanism: LRP1 is a multiligand endocytic receptor highly expressed on brain microvascular endothelial cells (BMECs) that undergoes rapid constitutive transcytosis. Its natural ligands include Aβ40/42, ApoE, and tissue plasminogen activator. LRP1-mediated transport can be hijacked by engineering therapeutic antibodies to bind LRP1 with mo
Weak Links:
Of the seven hypotheses evaluated, three emerge as sufficiently credible for prioritized development investment: H3 (pH-sensitive anti-TfR BsAb, 0.78), H7 (Focused Ultrasound, 0.88), and H6 (Nanobody-Fc Fusion via FcRn, 0.82). The skeptic's critiques substantially revise confidence downward for H2 (0.48), H5 (0.38), and H1 (0.62), though these should not be abandoned—rather deprioritized or reconceptualized. H4 (0.60) warrants intermediate-position investment with critical mechanistic validation mile
{
"ranked_hypotheses": [
{
"title": "Focused Ultrasound with Microbubble Contrast Agents for Antibody CNS Delivery",
"description": "FUS with systemically administered microbubbles induces localized, reversible BBB disruption via mechanical cavitation effects, triggering Akt phosphorylation and tight junction protein disassembly. When combined with therapeutic antibodies, synergistic brain penetration achieves 50-fold greater exposure than either approach alone. The technology leverages FDA-approved microbubble agents and MRI-guided targeting for spatial precision. Critical s
No clinical trials data available
Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.
No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.
Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.
High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.
Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.
Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
No DepMap CRISPR Chronos data found for LDLR (LDLR gene); ARH/DAB2 adaptor proteins.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No governance decisions recorded for this hypothesis.
Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.
Molecular pathway showing key causal relationships underlying this hypothesis
graph TD
FUS["FUS"] -->|causes| BBB_opening["BBB opening"]
FUS_1["FUS"] -->|activates| Src_kinase["Src kinase"]
FUS_2["FUS"] -->|causes| ZO_1_phosphorylation["ZO-1 phosphorylation"]
FUS_3["FUS"] -->|causes| tight_junction_disassembl["tight junction disassembly"]
FUS_4["FUS"] -->|activates| Akt_phosphorylation["Akt phosphorylation"]
FUS_5["FUS"] -->|enhances| anti_amyloid_antibody_bra["anti-amyloid antibody brain penetration"]
TFRC["TFRC"] -->|regulates| brain_endothelial_transcy["brain endothelial transcytosis"]
microbubble_cavitation["microbubble cavitation"] -->|causes| reversible_BBB_disruption["reversible BBB disruption"]
CLDN5_ZO_1_complex["CLDN5/ZO-1 complex"] -->|regulates| tight_junction_integrity["tight junction integrity"]
Focused_Ultrasound["Focused Ultrasound"] -->|causes| Blood_Brain_Barrier_Openi["Blood-Brain Barrier Opening"]
Focused_Ultrasound_6["Focused Ultrasound"] -->|activates| Src_Kinase_Activation["Src Kinase Activation"]
Focused_Ultrasound_7["Focused Ultrasound"] -->|causes| ZO_1_Phosphorylation["ZO-1 Phosphorylation"]
style FUS fill:#4fc3f7,stroke:#333,color:#000
style BBB_opening fill:#4fc3f7,stroke:#333,color:#000
style FUS_1 fill:#4fc3f7,stroke:#333,color:#000
style Src_kinase fill:#4fc3f7,stroke:#333,color:#000
style FUS_2 fill:#4fc3f7,stroke:#333,color:#000
style ZO_1_phosphorylation fill:#4fc3f7,stroke:#333,color:#000
style FUS_3 fill:#4fc3f7,stroke:#333,color:#000
style tight_junction_disassembl fill:#4fc3f7,stroke:#333,color:#000
style FUS_4 fill:#4fc3f7,stroke:#333,color:#000
style Akt_phosphorylation fill:#4fc3f7,stroke:#333,color:#000
style FUS_5 fill:#4fc3f7,stroke:#333,color:#000
style anti_amyloid_antibody_bra fill:#4fc3f7,stroke:#333,color:#000
style TFRC fill:#ce93d8,stroke:#333,color:#000
style brain_endothelial_transcy fill:#4fc3f7,stroke:#333,color:#000
style microbubble_cavitation fill:#4fc3f7,stroke:#333,color:#000
style reversible_BBB_disruption fill:#4fc3f7,stroke:#333,color:#000
style CLDN5_ZO_1_complex fill:#4fc3f7,stroke:#333,color:#000
style tight_junction_integrity fill:#4fc3f7,stroke:#333,color:#000
style Focused_Ultrasound fill:#4fc3f7,stroke:#333,color:#000
style Blood_Brain_Barrier_Openi fill:#4fc3f7,stroke:#333,color:#000
style Focused_Ultrasound_6 fill:#4fc3f7,stroke:#333,color:#000
style Src_Kinase_Activation fill:#81c784,stroke:#333,color:#000
style Focused_Ultrasound_7 fill:#4fc3f7,stroke:#333,color:#000
style ZO_1_Phosphorylation fill:#4fc3f7,stroke:#333,color:#000
neurodegeneration | 2026-04-02 | archived
No comments yet. Be the first to comment!